New Delhi, Nov 3 (PTI) Gland Pharma on Monday reported 12 per cent year-on-year increase in profit after tax (PAT) at Rs 184 crore for the September quarter, aided by strong performance by CDMO arm Cenexi.

The Hyderabad-based drug reported a PAT of Rs 163 crore for the July-September period of the previous fiscal year.

Revenue from operations rose to Rs 1,487 crore in the second quarter as compared with Rs 1,406 crore in the year-ago period, Gland Pharma said in a regulatory filing.

“We expect stronger momentum in the second half, driven by new launches and Cenexi’s recovery. Our investments in global CDMO expansion, capacity enhancement in high-end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for al

See Full Page